Artemis II Reaches the Moon and Rewrites the Distance Record: Artemis II entered one of the mission’s most historic phases as the crew prepared for humanity’s first lunar flyby since Apollo 17 in 1972. NASA astronauts Reid Wiseman, Victor Glover, Christina Koch, and CSA astronaut Jeremy Hansen awoke less than 19,000 miles from the Moon and received a recorded message from the late Apollo astronaut Jim Lovell, who linked their journey to Apollo’s legacy. During the flyby, Orion is set to break Apollo 13’s record for the farthest humans have traveled from Earth, reaching more than 252,000 miles away. The seven-hour observation period includes close study of lunar geology, an “Earthset” and “Earthrise,” a brief communications blackout behind the Moon, and a near hour-long solar eclipse from space, giving the crew a rare chance to observe the solar corona. (NASA)

Heart Digital Twins Move From Concept to Clinic: One of the week’s most intriguing health-tech stories came from cardiology: physicians used patient-specific “digital twins” of damaged hearts to plan ablation for ventricular tachycardia before touching the patient. In the 10-patient feasibility study reported in The New England Journal of Medicine, all patients were noninducible for VT at the end of the procedure, and the early follow-up looked encouraging. What makes this more than a clever software demo is the clinical logic: simulate the arrhythmia in silico, identify critical tissue, then burn less and aim better in the real heart. It is still a tiny, uncontrolled study, so caution is warranted. But it points toward a future in which imaging, modeling, and intervention become one workflow rather than separate domains. (New England Journal of Medicine)

Baxdrostat Offers New Hope for Resistant Hypertension: A major blood-pressure story also broke this week. Baxdrostat, an aldosterone synthase inhibitor, showed meaningful blood-pressure reductions in people with uncontrolled or treatment-resistant hypertension, according to a large international phase 3 trial highlighted April 3. The significance is not just another pill in a crowded field. Resistant hypertension is one of the most stubborn everyday problems in cardiovascular medicine, leaving patients exposed to stroke, heart attack, kidney disease, and premature death even while taking multiple drugs. Baxdrostat works upstream, targeting hormone signaling that drives salt and water retention. That mechanism matters because it suggests a more precise approach for a subset of patients whose hypertension is hormonally fueled. As always, real-world durability, cost, and side-effect management will shape impact, but this looks like one of the more consequential cardiometabolic developments of the week. (ScienceDaily)

Single-Shot Gene Therapy Restores Hearing in Congenital Deafness: A hearing-restoration story stood out for both emotional and scientific reasons. Researchers at Karolinska Institutet and collaborators reported that a single gene-therapy injection improved hearing in all 10 treated patients with congenital deafness or severe hearing loss tied to OTOF mutations. Some patients showed gains within a month, and the treatment appeared well tolerated. That matters because inherited deafness has long been discussed in the language of compensation and devices; gene therapy reopens the more radical possibility of repairing the underlying biology in at least some cases. The sample remains small, and this will need longer follow-up and broader testing across ages and mutation types. Still, it is one of the clearest signs yet that auditory gene therapy is moving from experimental promise toward reproducible human benefit. That makes it a genuinely important translational medicine story. (ScienceDaily)

A Few Minutes of Harder Movement May Matter More Than We Thought: Fitness news this week brought a useful corrective to the all-or-nothing way exercise is often discussed. Research publicized by the European Society of Cardiology found that among roughly 96,000 people, a higher proportion of vigorous activity was linked to lower risk of eight major diseases, including arthritis, heart disease, dementia, and type 2 diabetes. The point is not that everyone should suddenly become a high-intensity athlete. The more interesting message is that short bursts of exertion woven into ordinary life—climbing stairs fast, hurrying, carrying, pushing—may carry disproportionate benefits. That framing is important for public health because “I don’t have time” remains one of the central barriers to exercise. If vigorous “micro-efforts” count, the conversation shifts from ideal routines to usable realities. It is one of the week’s more practical health findings. (European Society of Cardiology)

FDA Approves a New Oral GLP-1 Weight-Loss Pill: The obesity-drug race accelerated again this week with FDA approval of Eli Lilly’s orforglipron, marketed as Foundayo. The agency said the decision came under its Commissioner’s National Priority Voucher pilot program and marked the first new molecular entity approved through that route. The practical significance is huge: another oral GLP-1 option could widen access for people unwilling or unable to use injectables, while intensifying competition in one of the hottest therapeutic markets in medicine. Reports this week emphasized convenience as a central selling point, because this pill can be taken without the food and timing constraints attached to some other oral options. The larger question now is whether more pills will simply expand the market or begin to force price and coverage changes that make obesity treatment materially more accessible. That is where this becomes a true health-systems story. (U.S. Food and Drug Administration)

Semaglutide’s Next Battle Is Not Biology but Budget: One of the most important obesity stories of the week was not about efficacy but economics. A new JAMA analysis, published online April 2, examined what semaglutide could mean for Medicare spending under voluntary price agreements. That may sound dry compared with clinical-trial headlines, but it gets at the real bottleneck in the GLP-1 era: not whether these drugs work, but whether large health systems can sustain paying for them at scale. Anti-obesity drugs are moving from niche metabolic tools toward population-level therapies with implications for diabetes, cardiovascular risk, and possibly more. That makes budget exposure a central policy issue. The stakes are especially high for Medicare because even modest changes in uptake translate into massive dollar shifts. In other words, obesity pharmacotherapy is now a reimbursement and public-finance story as much as a biomedical one. (JAMA Network)

Ambient AI Scribes Show Real Workflow Gains, With Caveats: Health AI produced a more grounded story this week than the usual hype cycle. A JAMA study and related editorial focused on ambient AI scribes—systems that listen during visits and draft clinical notes—found modest reductions in clinician EHR and documentation time across five academic health systems. The gains were real, but not magical: less paperwork, a slight increase in visit volume, and no sweeping solution to every form of burnout. That nuance is what makes the story valuable. Medicine does need relief from documentation overload, but tools like this will matter only if they improve workflow without introducing new accuracy, privacy, equity, or liability problems. So the headline is not “AI saves medicine.” It is that one narrow, burdensome part of clinical work may actually be getting better, and now the evidence base is slowly catching up to the sales pitch. (JAMA Network)

COVID’s U.S. Death Toll May Have Been Significantly Undercounted: A sobering public-health story emerged from JAMA this week: a new study suggests COVID-19 may have caused about 19% more U.S. deaths from March 2020 through December 2021 than official counts recorded. Using machine learning on death-certificate data, researchers estimated roughly 155,500 unrecognized COVID deaths on top of the approximately 840,000 officially reported during that period. The most important part of the story is not merely numerical revision. The undercount was described as systematically unequal, disproportionately affecting American Indian and Alaska Native, Asian, Black, and Hispanic populations, along with poorer counties and communities with worse baseline health. That means the historical record of the pandemic may also be a distorted record of inequity. Even years later, this still matters because mortality counts shape trust, policy evaluation, resource allocation, and how societies remember what happened. (JAMA Network)

CDC Testing Pauses Expose Fragility in U.S. Surveillance Capacity: A quieter but important public-health story came from CIDRAP: the CDC has temporarily paused testing for a range of pathogens, including poxviruses, some parasites, lymphocytic choriomeningitis, rabies, and mpox-related work, forcing state public-health labs to fill gaps. This is the kind of infrastructural story that rarely dominates headlines but often matters enormously in practice. Testing is not glamorous, yet it is what allows outbreaks to be recognized early and tracked accurately. When federal capacity wobbles, smaller jurisdictions can be left scrambling, especially where local labs lack staffing or specialized expertise. The significance here is broader than the specific pathogens listed. It is a reminder that surveillance systems are only as strong as their least visible components. In a period already marked by stress on U.S. public-health institutions, even temporary pauses carry outsized implications for preparedness and confidence. (CIDRAP)

Microplastics Move Closer to the Center of U.S. Health Policy: One of the week’s most consequential environmental-health developments came from EPA and HHS. On April 2, the agencies announced that microplastics will, for the first time, be included as a priority contaminant group on EPA’s draft Sixth Contaminant Candidate List for drinking water, while HHS’s ARPA-H launched a $144 million STOMP program focused on measuring exposure and developing ways to reduce microplastics in the human body. The immediate policy effect is not a national safety standard tomorrow; the candidate list is a research-and-regulatory precursor, not a ban. But symbolically and institutionally, this is a shift. Microplastics are moving from diffuse concern to formal federal target. That matters because once a pollutant enters the machinery of monitoring, funding, and rulemaking, it becomes harder to dismiss as speculative background noise. This is how emerging health hazards start becoming governable. (US EPA)

IMAGE CREDIT: NASA.